Atrial fibrillation - dabigatran etexilate (TA249)
NICE recommends dabigatran etexilate as a possible treatment to prevent stroke and systemic embolism in people with atrial fibrillation.
Who can have dabigatran etexilate?
You should be able to have dabigatran etexilate if you have a type of atrial fibrillation known as nonvalvular and at least one of the following applies:
- you have had a stroke, transient ischaemic attack (mini stroke) or embolism in the past
- your heart pumps less blood around your body than normal
- you have symptoms of heart failure of New York Heart Association class 2 or above (mild shortness of breath and/or chest pain, and slight limitation during ordinary activity)
- you are 75 or older
- you are 65 or older and have diabetes, coronary artery disease or high blood pressure.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommends dabigatran etexilate because its cost is justified by the benefits it provides compared with other treatments available on the NHS.
This page was last updated: 10 March 2014
- Web format
- Full Guidance (PDF)
- TA249 Dabigatran etexilate ar gyfer atal str˘c ac emboledd ymhlith pobl Ô ffibriliad atr´aidd: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.